Advances in blood–brain barrier-crossing nanomedicine for anti-glioma

Cancer Nanotechnology

Review

Wenqing Hong¹  Haisheng Qian²  Xianwen Wang³  Dongdong Liu⁴  Hu Zhou⁵  Zhenchao Tao⁵  Xingliang Dai⁶  Hongwei Cheng⁶ 

[1] Department of Health Management Center, The First Affiliated Hospital of Anhui Medical University, 230032, Hefei, People’s Republic of China;Department of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, 230032, Hefei, People’s Republic of China;Department of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, 230032, Hefei, People’s Republic of China;College and Hospital of Stomatology, Key Lab. of Oral Diseases Research of Anhui Province, Anhui Medical University, 230032, Hefei, People’s Republic of China;Department of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, 230032, Hefei, People’s Republic of China;School of Biomedical Engineering, Research and Engineering Center of Biomedical Materials, Anhui Medical University, 230032, Hefei, People’s Republic of China;Department of Radiation Oncology, Anhui Provincial Cancer Hospital, 230031, Hefei, People’s Republic of China;School of Biomedical Engineering, Research and Engineering Center of Biomedical Materials, Anhui Medical University, 230032, Hefei, People’s Republic of China;

关键词: Glioma;    Chemotherapy;    Nanomedicine;    Blood–brain barrier;    Combination therapy;   

DOI  :  10.1186/s12645-023-00211-9

 received in 2022-07-16, accepted in 2023-05-04,  发布年份 2023

来源: Springer

【 摘 要 】

Glioma is the most prevalent type of primary brain tumor, and glioblastoma multiforme (GBM) is the highest and most deadly type of primary central nervous system (CNS) tumor, affecting a significant number of patients each year, with a median overall survival of approximately 14.6 months after diagnosis. Despite intensive treatment, nearly all GBM patients experience recurrence, with a 5-year survival rate of about 5%. The protective BBB and high tumor heterogeneity prevent the effective delivery of drugs, resulting in the treatment failure of various drugs. The emergence of nanometer-scale diagnosis and treatment methods has provided new promising approaches to overcome these difficulties. Thus, our review focuses on the development ofBBB-crossing nanomedicine-enhanced chemotherapy and combined therapy applications for glioma. Meanwhile, we also reviewed the strategies to overcome the blood–brain barrier. Additionally, we discuss recent achievements in the area of brain tumor treatment with nanomedicine and the rational design approach, which will offer recommendations for anti-GBM nanomedicine development.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

40517_2023_258_Article_IEq121.gif

Fig. 5

41116_2023_36_Article_IEq701.gif

41116_2023_36_Article_IEq639.gif

Fig. 3

41116_2023_36_Article_IEq450.gif

41116_2023_36_Article_IEq427.gif

41116_2023_36_Article_IEq414.gif

41116_2023_36_Article_IEq404.gif

41116_2023_36_Article_IEq396.gif

41116_2023_36_Article_IEq392.gif

41116_2023_36_Article_IEq389.gif

41116_2023_36_Article_IEq359.gif